Trial Profile
A Multicenter Joint Phase II Clinical Study to Evaluate the Efficacy and Safety of Dasatinib Very Low Dose Therapy in Elderly Patients with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2022
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms DAVLEC
- 14 Dec 2021 Primary endpoint (Major molecular response (MMR) achievement rate at 12 months after initiation of treatment) has been met, as per results presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 14 Dec 2021 Results assessing the efficacy and safety of a reduced initial dose of DAS (20 mg/day) in the elderly with chronic phase chronic myeloid leukemia , presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 07 Nov 2021 Planned number of patients changed from 100 to 50.